This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Atara Biotherapeutics (ATRA) in Focus: Stock Moves 6.9% Higher
by Zacks Equity Research
Atara Biotherapeutics (ATRA) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
Alexion's Soliris Successful in Phase III Study for NMOSD
by Zacks Equity Research
Alexion's (ALXN) efforts to expand lead blockbuster drug Soliris' label gets a boost as the phase III study on the drug for the indication of NMSOD was successful.
AnaptysBio (ANAB) Looks Good: Stock Adds 9.9% in Session
by Zacks Equity Research
AnaptysBio (ANAB) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
Is First Trust Multi Cap Growth AlphaDEX Fund (FAD) a Hot ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FAD
Major Stock Indexes Approaching Record Highs: 5 Top Picks
by Nalak Das
The three major stock market indexes ??? the Dow 30, S&P 500 and Nasdaq Composite ??? are at present within the striking distance to achieve their all-time high level.
Cytori's Chemotherapy Candidate Gets Orphan Drug Status
by Zacks Equity Research
Cytori Therapeutics' (CYTX) chemotherapy candidate, ATI-1123, gets orphan drug status from the FDA for small cell lung cancer.
AngioDynamics (ANGO) to Acquire RadiaDyne, Boost Oncology
by Zacks Equity Research
AngioDynamics' (ANGO) agreement to acquire RadiaDyne is expected to close by the end of September. The RadiaDyne acquisition will expand the Oncology segment.
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Illumina, Celgene , Athersys and Achillion
DENTSPLY Launches Azento, Improves Digital Implant Workflow
by Zacks Equity Research
DENTSPLY's (XRAY) Azento is a unique dental platform that will help dentists select the best-fitting implant, optimal implant positioning and feasible healing environment.
IPOs and Foreign Investment Propel Biotech: 4 Top Picks
by Nitish Marwah
A steady influx of foreign as well as domestic investments in U.S. biotech has gone a long way in boosting gains for the space.
Allscripts' Sunrise Abstracting Selected by Wyckoff Heights
by Nabaparna Bhattacharya
Allscripts' (MDRX) Sunrise Abstracting Solution gets picked by Wyckoff Heights Medical Center. The platform complements Allscripts Sunrise electronic health record unit.
Is Illumina (ILMN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (ILMN) Outperforming Other Medical Stocks This Year?
Should You Invest in the ARK Genomic Revolution Multi-Sector ETF (ARKG)?
by Sweta Killa
Sector ETF report for ARKG
Here's Why You Should Hold On to DaVita (DVA) Stock Now
by Zacks Equity Research
Strong prospects in the Kidney Care segment to drive DaVita (DVA) stock over the long haul.
Thermo Fisher to Acquire BD's Advanced Bioprocessing Unit
by Zacks Equity Research
BD's (BDX) Advanced Bioprocessing business generates revenues worth $100 million annually. The unit will be integrated in the Thermo Fisher's (TMO) Life Sciences Solutions Segment.
OPKO Health (OPK) Begins RAYALDEE Phase 2 Clinical Trial
by Zacks Equity Research
OPKO Health's (OPK) consistent focus on enhancing the efficacy of its flagship RAYALDEE platform is likely to lend it a competitive edge in the MedTech space.
Inovio Initiates Dosing in Phase I/IIa Study on MERS Vaccine
by Zacks Equity Research
Inovio Pharmaceuticals (INO) administers dosage in the first patient under a phase I/IIa trial to assess its MERS vaccine INO-4700.
ProQR Up More Than 120% on Favorable Eye Disorder Study Data
by Zacks Equity Research
ProQR Therapeutics (PRQR) presents positive data from a phase I/II study on QR-110, its lead pipeline candidate for LCA 10, the most common genetic cause of visual impairment in kids.
Puma Biotech Gets EU Nod for Breast Cancer Drug Nerlynx
by Zacks Equity Research
Puma Biotech (PBYI) gains EU approval for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
Neogen's Livestock Genetic Buyout Expands Animal Safety Suite
by Zacks Equity Research
The acquisition of Livestock Genetic will position Neogen (NEOG) as a leading agrigenomics company worldwide.
MannKind Stock Up on Licensing Deal With United Therapeutics
by Zacks Equity Research
MannKind (MNKD) out-licenses rights to its investigational dry powder formulation of treprostinil to United Therapeutics for treating pulmonary arterial hypertension.
HealthEquity (HQY) Beats Q2 Earnings & Revenue Estimates
by Zacks Equity Research
Strong HSA Member growth boosts HealthEquity's (HQY) results in Q2. A strong guidance raises investors??? optimism.
Inovio (INO) Initiates Phase I Study on Hepatitis C Vaccine
by Zacks Equity Research
Inovio Pharmaceuticals (INO) and Korean partner GeneOne Life Science dose the first patient in a phase I study, which will assess its hepatitis C vaccine GLS-6150.
Zacks.com highlights: Buckle, Illumina, Surmodics and Huntington Ingalls Industries
by Zacks Equity Research
Zacks.com highlights: Buckle, Illumina, Surmodics and Huntington Ingalls Industries
Here's Why You Should Hold On to Baxter (BAX) Stock Now
by Zacks Equity Research
Baxter's (BAX) cyclophosphamide performance continues to remain dismal. Nevertheless, the company witnesses positive tidings of other products on the regulatory front.